This result confirmed the higher immunogenicity of colonic tumour cells with MMR gene deficiency and suggested a possible clinical use of oxidative stress to enhance immune response to CRC besides the existing immunotherapy trial [35]. The gene discussed is MRC1; the disease is digestive system cancer.